The Assistance Fund: Immunoglobulin A Nephropathy (IgAN)

The Assistance Fund: Immunoglobulin A Nephropathy (IgAN) program provides financial assistance for individuals prescribed FDA-approved treatments like Tarpeyo, Filspari, or Fabhalta. It covers copays, coinsurance, deductibles, health insurance premiums, and other eligible incidental medical expenses. Eligibility is for commercially insured, Medicare, or Medicaid patients residing in the US and Puerto Rico, based on income guidelines.

Eligibility

Applicants must be residents of the US or Puerto Rico who are prescribed FDA-approved treatments for IgA Nephropathy and have commercial or government insurance. This needs-based program provides financial support for copays, coinsurance, deductibles, and eligible incidental medical expenses.